Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Sobh on the Therapeutic Potential of Selectively Targeting NSD2 in Multiple Myeloma

May 19th 2025

Armin Sobh, PhD, discusses the therapeutic potential of selectively targeting NSD2 in the treatment of multiple myeloma.

Dr Konstantinopoulos on the Safety of Letrozole, Abemaciclib, and Metformin in ER+ Recurrent Endometrial Cancer

May 19th 2025

Panagiotis A. Konstantinopoulos, MD, PhD, discusses the safety of letrozole, abemaciclib, and metformin in ER-positive, recurrent endometrial cancer.

postMONARCH ctDNA Analysis Underscores Benefit of Abemaciclib Plus Fulvestrant in HR+ Advanced Breast Cancer

May 19th 2025

An exploratory ctDNA analysis from postMONARCH highlighted the benefit of abemaciclib plus fulvestrant across HR-positive breast cancer subgroups.

FDA Approval of Perioperative Durvalumab Plus Chemo Supports the Efficacy of a Novel MIBC Management Approach

May 19th 2025

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Tucatinib/Trastuzumab Yields Durable Responses in HER2-Mutated Metastatic Breast Cancer

May 19th 2025

Final analysis of SGNTUC-019 showed a 41.9% ORR, an 80.6% DCR, and a 18.2-month DOR with tucatinib/trastuzumab in pretreated, HER2-mutated metastatic breast cancer.

Dr Maroto-Martin on the Development of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 16th 2025

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

Dr Garcia on the Safety of Earlier Use of Lu 177 Vipivotide Tetraxetan PSMA+ mCRPC

May 16th 2025

Jorge A. Garcia, MD, discusses the safety of Lu 177 vipivotide tetraxetan earlier in the treatment course for PSMA–positive mCRPC.

Dr Pimenta on Ongoing Therapeutic Challenges in Soft Tissue Sarcomas

May 16th 2025

Erica Maria Pimenta, MD, discusses ongoing therapeutic and translational challenges in the treatment of soft tissue sarcomas.

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

May 16th 2025

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Bireociclib Earns NMPA Approval in China For 2 Indications in HR+/HER2– Breast Cancer

May 16th 2025

China’s NMPA approved bireociclib for 2 indications in adult patients with HR+/HER2– breast cancer.

Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer

May 16th 2025

An analysis from PADA-1 showed the emergence of ESR1 mutations was uneven over time in hormone receptor–positive, HER2-negative metastatic breast cancer.

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

May 15th 2025

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

May 15th 2025

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC

May 15th 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Dr Grisham on the FDA Approval of Avutometinib/Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer

May 14th 2025

Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma

May 14th 2025

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Dr Perez on the FDA Approval of Belzutifan for Advanced Pheochromocytoma and Paraganglioma

May 14th 2025

Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Dr Dorff on a Real-World Study of Relugolix in Advanced Prostate Cancer

May 13th 2025

Tanya B. Dorff, MD, discusses the clinical characteristics and treatment preferences for initiating relugolix during prostate cancer treatment

Dr Hong on the FDA Approval of Larotrectinib for NTRK+ Solid Tumors

May 13th 2025

David S. Hong, MD, discusses the FDA’s full approval of larotrectinib for patients with solid tumors harboring an NTRK gene fusion.

Dr Chiappori on the Role of Ensartinib for ALK+ NSCLC With CNS Metastases

May 13th 2025

Alberto Chiappori, MD, discusses the inclusion of patients with CNS metastases in the eXALT3 trial of ensartinib in ALK-positive NSCLC.